H.C. Wainwright initiated coverage on CRISPR Therapeutics with a new price target
$CRSP
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
H.C. Wainwright initiated coverage of CRISPR Therapeutics with a rating of Buy and set a new price target of $65.00